Navigation Links
Owners Reminded That Pets Need Dental Care, Too
Date:1/8/2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/9/2009)...Call/ -- Mach One Corporation,(Pink Sheets: MNCN)...ducts,that produce a positive long term benefit t... today that it has entered into a non-binding lett...roposed transaction with Ceres,Organic Harvest, I...ng shares,of the Seller. , The proposed tr...
(Date:1/9/2009)...all/ - Hard to Treat Diseases (HTDS) www.htdsmedi...erger with Slavica Bio Chem (Formerly ReNuYu Bioch... pay for the Slavica merger and the pending China ...million non-dilatable restricted shares to be dist...erbia research. Key medical consultants and X ReNu...
(Date:1/9/2009)...m, PA announced that a new Hydrophilic Coatings b...mpany,s website that provides a forum where medica...d the latest developments in device coating techno...ews. , Horsham, PA (PRWEB...nnounced that a new Hydrophilic Coatings blog has ...
(Date:1/9/2009)...a Massachusetts-based designer and producer of cus...d vaccine discovery organizations worldwide, is pr...ons in the face of the global shortage of acetonit...ge of new solutions are two leading peptide expert... Gardner, MA (PRWEB) January 9...
Breaking Medicine News(10 mins):Health News:Mach One Corporation Enters Letter of Intent to Acquire Ceres Organic Harvest, Inc. 2Health News:Hard To Treat Diseases (HTDS) Recapitalization 2Health News:Blog Launched to Discuss Developments in Hydrophilic Coatings for Medical Devices 2Health News:New Experts Help New England Peptide Combat Global Acetonitrile Shortage; Company Integrating Cost-Effective Chemical Solvent Alternatives 2Health News:New Experts Help New England Peptide Combat Global Acetonitrile Shortage; Company Integrating Cost-Effective Chemical Solvent Alternatives 3
...ws that Soy milks, yogurts and desserts grew by 22...e even more health-conscious and more aware of foo...at based on the current trend sales are further ex.... According to the survey researchers also say the...
...the difference in genes might be responsible for t...yperactivity disorder (ADHD) differ in reacting to...s from University of Illinois at Chicago, had foun... a dopamine transporter gene -- a variant known to...
...e (TAI) will soon begin training sex workers in th...as been accelerated following the provision of $12...ve years. // The decision to train sex workers on ...been taken up after the representatives of sex wor...
...e nearly twice as prevalent in high schools in the...iddle school students admit that drugs are used, k...schools where drugs are widely available are three...marijuana and twice as likely to use alcohol than ...
Other Medicine News:
(Date:1/9/2009)...wire-FirstCall/ -- ProUroCare Medical Inc. (OTC Bu...of 3,050,000 units at $1.00 per unit, each unit co...emable warrant to purchase one share of common sto...mpany has granted the underwriter of the offering ...7,500 units to cover over-allotments, if any. The ...
(Date:1/9/2009)...re/ -- ESBATech AG, a leading developer of antibod...ation of the Phase I/IIa clinical development of i...eoarthritis (OA). This double-blind, randomized, p...signed to investigate the safety, tolerability and... intra-articular administration to patients with s...
(Date:1/8/2009)...wswire-FirstCall/ -- , - ThromboGenics, Lea...omacular Adhesion in the US and Europe , Th...nology company,focused on innovative treatments f...unces today that it has started the Phase III clin... treatment of back of the eye disease, the,final ...
(Date:1/8/2009)... second indication with clinical-stage, systemical...EMONT, Calif., Jan. 8 Quark Pharma...l company discovering and developing novel RNA int...ed that it has initiated patient dosing in its Pha... administered siRNA drug candidate QPI-1002 (previ...
Breaking Medicine Technology:ProUroCare Medical Inc. Announces Pricing of Equity Offering 2ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity 2ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity 3ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity 4ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease 2ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease 3ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease 4Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function 2Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function 3Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function 4Tips from the Journals of the American Society for Microbiology 107 1Tips from the Journals of the American Society for Microbiology 107 2Tips from the Journals of the American Society for Microbiology 107 3Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer 109 1Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer 109 2St Jude influenza survey uncovers key differences between bird flu and human flu 106 1St Jude influenza survey uncovers key differences between bird flu and human flu 106 2St Jude influenza survey uncovers key differences between bird flu and human flu 106 3Stanford study highlights cost effective method of lowering heart disease risks 104 1Stanford study highlights cost effective method of lowering heart disease risks 104 2Stanford study highlights cost effective method of lowering heart disease risks 104 3
...ent with ISIS 301012 produced at least 45% additio...ded to,maximally-tolerated lipid-lowering therapie...tCall/ -- Isis,Pharmaceuticals, Inc. announced upd...al of ISIS 301012 in patients with homozygous,fami...of which were,presented in March at the of Cardiol...
...from Phase III pivotal trial demonstrate safety an...rol fumarate for,patients with moderate to severe ...- Dey, L.P. announced,that two clinical data prese...ence of the American Thoracic Society (ATS) on,Sun...o. The,presentations will detail Phase III clinica...
Other Medicine Technology:Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 2Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 3Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 4Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 5Clinical Trial Data for Perforomist Inhalation Solution to be,Presented at ATS on May 20, 2007 2Clinical Trial Data for Perforomist Inhalation Solution to be,Presented at ATS on May 20, 2007 3Clinical Trial Data for Perforomist Inhalation Solution to be,Presented at ATS on May 20, 2007 4
The PK Plasma-CISE™ (wire electrodes) and Plasma-CUT™ (coiled electrodes) are single use devices that produce precise, consistent tissue cutting with minimal thermal spread and Vapor seal
...gle use device that produces rapid, consistent, pr...nd vapor sealing of adjacent tissue for prostatic ...ccation. Often referred to as PlasmaKinetic vapori...the urologist the control needed to achieve the an...
Medium Surgical Clips. 6 clips per cartridge. Box of 30 cartridges with a total of 180 titanium clips per box. For secure vasal and other occlusion.
Sterile Disposable Thermal Cautery Tips for Vasectomy. Individually peel-pouched with dual plastic sheaths to cover non-sterile handle. Box of 10 tips.
Medicine Products: